Basel Startups to Watch in 2027: Verified Biotech, Radiopharma, Health Marketplace and AI Health Companies, Where They Get Support and What Changed
Basel is one of the world's most concentrated life sciences cities: Roche and Novartis have their headquarters here, the University of Basel and an ETH Zurich department are in town, and France and Germany are a tram ride away. Its startups reflect that. Most of the young companies worth watching develop medicines, and in 2026 several of them signed large pharma deals, raised big rounds or moved into later clinical trials. The 2026 version of this article listed ten names. When we checked them, only one was really a Basel company: two are based in Lausanne, one appears to be Icelandic, one has no website we could find, and five were generic names, not real companies. For this 2027 edition we started again. Every company below gives a Basel or Allschwil address on its own website, and every fact comes from the company's own pages and press releases, checked in November 2026. Funding figures we found only on the BaseLaunch portfolio page are labelled as such.
Quick answer: the Basel startups to watch in 2027 are Windward Bio (asthma and COPD antibodies, a $165 million round in May 2026 and a Phase 3 start), Alentis Therapeutics (claudin-1 drugs, a US$355 million upfront deal with CSL in October 2026), Nuclidium (copper-based cancer radiopharmaceuticals, CHF 105 million Series B), TOLREMO, Synendos, Anaveon, Engimmune, Versameb, the health products marketplace Axmed and the AI baby cry analysis company Zoundream. Founders get support from Basel Area Business & Innovation, BaseLaunch, DayOne and Switzerland Innovation Park Basel Area.
Are you getting customers from ChatGPT yet?
More and more traffic is coming from Perplexity, ChatGPT, Grok and other AI tools.
👉 Rank on ChatGPT
Why Basel Matters for Founders in 2027
Basel's startup scene runs on three things. The first is pharma know-how: Roche is a partner of the BaseLaunch company builder, Anaveon's new science chief came from Actelion, Idorsia and Roche, and global drug companies are the natural buyers and partners for young biotechs, as CSL's deal with Alentis showed in October 2026. The second is a dense support system: Basel Area Business & Innovation runs programmes that offer between CHF 50,000 and CHF 500,000 of founder funding, and Switzerland Innovation Park Basel Area rents labs to young companies, so a team can start experiments without building its own lab. The third is the border: Basel Area Business & Innovation presents the region as the place where Switzerland, France and Germany meet, with access to three markets. The flip side is focus. Almost all the strong young companies we found are in life sciences; we did not find a Basel fintech or cleantech startup we could verify well enough to list.
For the bigger picture, compare our guides to the best countries for startups in Europe, the deep tech cities in Europe and the European startup ecosystem country by country.
Basel Startups to Watch in 2027 Compared
Sources: each company's official website, contact or imprint page and own press releases, checked 6 November 2026; amounts marked BaseLaunch come from the BaseLaunch portfolio page. Amounts are in the currency of the announcement.
The Basel Startups to Watch in 2027
1. Windward Bio: from launch to Phase 3 in under two years
Windward Bio was founded in 2024 by Luca Santarelli, who is its CEO and board chair, and is headquartered at Aeschenplatz 6 in Basel, with operations in the United States. It develops ultra-long-acting antibodies for asthma, COPD and atopic dermatitis. Its lead drug, WIN378, blocks a signal called TSLP; a second drug, WIN027, targets both TSLP and IL-13. Windward launched with a $200 million Series A in January 2025, announced a $165 million crossover financing on 4 May 2026, and on 8 September 2026 reported positive Phase 2 results in asthma with dosing twice a year, and started Phase 3. Its site says a second pivotal asthma trial, POLARIS-2, is planned for the first half of 2027.
Lesson for founders: Windward launched with an antibody that was already ready for Phase 2 trials instead of starting from scratch. Buying time with a later-stage asset is a strategy, not a shortcut.
2. Alentis Therapeutics: the claudin-1 company
Alentis Therapeutics calls itself the claudin-1 company: it develops antibodies and antibody-drug conjugates (ADCs) against claudin-1, a protein involved in fibrosis and in several cancers. Its antibody lixudebart is in a Phase 2 study in a rare kidney disease (ANCA-associated vasculitis with kidney involvement), and two ADCs are in the clinic for cancer. On 5 October 2026 Alentis and CSL announced a global partnership for lixudebart: CSL makes an initial payment of US$355 million, Alentis can receive up to US$1.2 billion more in commercial milestones, the two share global profits, and CSL funds the planned Phase 3 trial. On 14 October 2026 it also signed an ADC collaboration with the Korean company PinotBio. Alentis gives its address as Hegenheimermattweg 167A in Allschwil, the Switzerland Innovation Park Basel Area campus on the city's edge. BaseLaunch, which helped build it, lists $366 million raised.
Lesson for founders: Alentis bet everything on one biological target and kept finding new uses for it. Depth on one idea can be worth more than a broad, shallow pipeline.
3. Nuclidium: copper instead of lutetium
Nuclidium develops radiopharmaceuticals for cancer based on copper isotopes: copper-61 for imaging and copper-67 for therapy. On 27 May 2026 it closed a CHF 26 million Series B extension, bringing the round to CHF 105 million. In October 2026 it was named to the Fierce 15 list, imaged the first patient in a Phase 2 study of its 61Cu-NU101 diagnostic in metastatic prostate cancer, and signed a long-term partnership with NorthStar Medical Technologies to produce copper-67. Its site gives Nuclidium AG at Bäumleingasse 18 in Basel, with a German subsidiary in Munich.
Lesson for founders: Nuclidium secured its supply chain, the isotope itself, as early as its science. In hard tech, a weak supplier can stop you as surely as a failed trial.
Boost Your SEO by Getting Featured in Our Blogs and get a backlink.
We publish content about startups, education, tech, funding, etc. that ranks well not only in Google but also in Perplexity, ChatGPT, Grok and other AI tools.
👉 Get featured now!
4. TOLREMO therapeutics: stopping cancer drug resistance
TOLREMO therapeutics works on why targeted cancer drugs stop working. Its drug TT125-802 is an oral inhibitor of CBP/p300, proteins that help cancer cells switch on resistance genes. TOLREMO raised a USD 39 million Series A in September 2023 with a strategic investment from Pierre Fabre Invest, received two FDA Fast Track designations in lung cancer in August 2025, and on 15 September 2026 announced it had completed its Phase I study and presented final data at the World Conference on Lung Cancer. Its CEO, Stefanie Flückiger-Mangual, is one of the scientific founders and led the team that discovered the mechanism. Its imprint gives Hochbergerstrasse 60C in Basel.
Lesson for founders: TOLREMO's science came from its founder's own lab work, and she still runs the company. Scientist founders can lead, not only advise.
5. Synendos Therapeutics: a new kind of anxiety drug
Synendos Therapeutics was founded in Basel in 2019 by Prof. Jürg Gertsch, Dr. Andrea Chicca (now CEO) and Dr. Simon Russell, out of research at the University of Bern. It targets the brain's endocannabinoid system; its first drug, SYT-510, completed Phase 1 studies in 2025. On 20 May 2026 it started dosing patients in a Phase 2 trial in generalized anxiety disorder, run with Professor Allan Young, and expects preliminary data in early 2027. Its board is chaired by Prof. Jutta Heim, and its contact page gives Barfüsserplatz 3 in Basel. BaseLaunch lists $25 million raised.
Lesson for founders: Synendos picked one condition with a clear unmet need to test a broad platform. Narrow first trials make a big idea easier to prove.
6. Anaveon: resetting the immune system
Anaveon develops engineered antibodies for autoimmune diseases. Its lead, ANV200, is designed to remove the immune cells that carry PD-1 and drive chronic inflammation; it is in preclinical development, with clinical testing planned. In July 2026 it appointed Laetitia Pouzol, formerly of Actelion, Idorsia and Roche, as Chief Scientific Officer. Its site gives Hochbergerstrasse 60C in Basel. BaseLaunch's portfolio page, which still describes Anaveon's earlier cancer work, lists $155 million raised.
Lesson for founders: Anaveon changed its main disease area and kept going. A strong team and platform can survive a pivot that a single product could not.
Boost Your SEO by Publishing Your Startup Press Release with us.
We publish content about startups, education, tech, funding, etc. that ranks well not only in Google but also in Perplexity, ChatGPT, Grok and other AI tools.
👉 Publish Press Release
7. Engimmune Therapeutics: AI-designed T-cell receptor drugs
Engimmune was founded in 2021 on inventions by Dr. Rodrigo Vazquez-Lombardi, now its CEO, and Prof. Sai Reddy. It develops soluble T-cell receptor (TCR) drugs for solid tumours and uses AI-guided protein engineering to make them bind more strongly and stay stable. It closed a seed round in May 2022 co-led by Pureos Bioventures and Novo Holdings; BaseLaunch lists $16 million raised. Its lead programme is preclinical. Its contact page gives c/o Switzerland Innovation Park Basel Area in Allschwil.
Lesson for founders: Engimmune uses AI as a tool inside a lab, not as the product. Investors fund AI that shortens a real experiment, not AI as a label.
8. Versameb: RNA medicines from Basel
Versameb develops RNA therapeutics, including messenger RNA that tells the body's own cells to make a healing protein. In March 2025 it described itself as a clinical-stage company when it announced its first patent in China. Its imprint names Versameb AG at Hochbergerstrasse 60C in Basel, with Klaas Pieter Zuideveld as CEO; BaseLaunch lists $35 million raised.
Lesson for founders: Versameb protects its technology country by country. Patents in the markets you plan to sell in are part of the product.
9. Axmed: a marketplace for medicines in low- and middle-income countries
Axmed is a B2B marketplace where hospitals, ministries and clinics in low- and middle-income countries buy medicines and health products, with pricing, financing and delivery in one place. The old article called it a surgical robotics company; it is not. Axmed says it is a social impact health-tech venture and public benefit corporation, caps its markup at 10%, and reached 4.2 million patients in 2025. It was incorporated in August 2023, raised seed funding from Founderful in May 2024, and opened a regional headquarters in Nairobi in December 2024. In February 2026 it announced a $6 million grant from the Gates Foundation, in October 2026 ViiV Healthcare announced an agreement to make its HIV medicines available through Axmed in more than 50 middle-income countries, and according to Fast Company it ranked second in healthcare in the magazine's Most Innovative Companies of 2026. Its headquarters is at Grosspeteranlage 29 in Basel.
Lesson for founders: Axmed publishes its markup and its impact numbers. In a market where buyers distrust middlemen, transparency is the product.
10. Zoundream: what a baby's cry can tell doctors
Zoundream uses AI and sound analysis to read baby cries, first to tell parents what a baby needs and, in its research, to spot early signs of neurodevelopmental problems. In October 2026 it received a grant from Spain's Red.es for NEODREAM, a two-year study with hospitals in paediatrics and neonatology, and in November 2026 co-founder Ana Laguna Pradas presented early results from 93 infants at the CEPAS2026 paediatrics congress in Lyon. Zoundream AG is based at Switzerland Innovation Park Basel Area, Lichtstrasse 35 in Basel, with a second office in Barcelona; its CEO Roberto Iannone is quoted on the Basel Area site thanking the local network for its support.
Lesson for founders: Zoundream started with a consumer problem every parent knows and built clinical research on top. A simple first use case can open the door to a medical one.
Is your startup on ChatGPT?
More and more traffic is coming from Perplexity, ChatGPT, Grok and other AI tools.
👉 Rank on ChatGPT
Where Basel Startups Get Support
- Basel Area Business & Innovation: the regional innovation agency for the cantons around Basel. Its startup offer, called Launch, includes coaching through VentureConnect, the Digital Accelerator Basel (four startups and one theme a year, for digital, AI and data startups), InnoJura for manufacturing startups, and funding programmes worth between CHF 50,000 and CHF 500,000.
- BaseLaunch: the Basel Area's biotech company builder. It offers up to CHF 500,000 in financing, access to partners such as Roche and to investors, and lab space where needed. It says its portfolio has raised over $1.5 billion; T3 Pharma, one of its companies, was acquired by Boehringer Ingelheim for $507 million. Its next application deadline is 8 January 2027.
- DayOne: a non-profit healthtech accelerator in Basel for early-stage tech startups that solve problems in pharma research and development. Its three-month hybrid programme is global and gives non-dilutive grants, mentoring and pharma introductions with no equity and no fees; DayOne NEXT supports the best teams afterwards. The Basel Area site puts its funding at up to CHF 50,000.
- Switzerland Innovation Park Basel Area: labs, private offices and coworking on several campuses, including the Main Campus in Allschwil, a site on the Novartis Campus in Basel and one in the Jura. Alentis, Engimmune and Zoundream are based on its campuses.
Women founders can also look at the programmes in our lists of accelerators for female entrepreneurs in Europe and grants for female entrepreneurs in Europe. Basel already has role models: TOLREMO's CEO Stefanie Flückiger-Mangual co-founded the company, Ana Laguna Pradas co-founded Zoundream, and Prof. Jutta Heim chairs the Synendos board.
What Changed Since the 2026 List
Only Axmed from the old list is a real company with its headquarters in Basel, so it stays, with a corrected description. The other nine are gone:
- Evolytes: a real edtech company, but we found no Basel base, and it appears to be an Icelandic company.
- MindMaze: its own site gives its headquarters in Lausanne, not Basel.
- DPhi Space: an active space startup (it put an AI model on a satellite in 2026), but its job ads and press releases place it in Lausanne. It is a space company, not the "AI deep learning" firm the old article described.
- CellX Biosolutions: we found no website or other evidence of a Basel company with this name.
- "Cleantech Pioneers", "NomX AI Solutions", "BioFuturistics", "Swiss FinTech Innovators" and "Agro-Tech Basel": generic labels, not companies we could find.
- Axmed: it is a marketplace for medicines and health products, not a surgical robotics company.
- Removed figures: the old "25,000 tech graduates a year" and venture capital numbers had no source.
Which Basel Startup Should You Learn From?
- You build a drug or therapy company: study Windward Bio, which started with a Phase 2-ready asset, and Alentis, which turned one target into a large pharma deal.
- You come from a university lab: study TOLREMO and Synendos, both founded by the scientists behind the research.
- You build hard tech with a supply chain: study Nuclidium and its isotope supply partnership.
- You use AI in science: study Engimmune, where AI speeds up protein engineering, and Zoundream, where AI turns sound into clinical data.
- You build a marketplace or impact business: study Axmed, which combines grants, pharma partners and a capped markup.
- You need to change direction: study Anaveon, which moved from cancer to autoimmune disease.
How Founders Use Basel's Startup Scene
Look at who backs these companies: Alentis has CSL as a partner, Synendos has Sunstone, Kurma and Ysios on its board, Engimmune was seeded by Pureos Bioventures and Novo Holdings, and Axmed by Founderful and the Gates Foundation. If you build technology, compare them with the investors in our guides to deep tech VCs in Europe and deep tech angel investors in Europe, and look at BaseLaunch and DayOne next to the programmes in our lists of startup incubators in Europe and deep tech accelerators in Europe.
Meet the community at the best startup events in Switzerland, the top biotech startup events and the top healthtech startup events. Comparing cities? Basel's neighbour in our series is Zurich startups to watch, which covers ETH Zurich spin-offs in climate tech, robotics and fintech; nearby, see Munich startups to watch, Innsbruck startups to watch and Aachen startups to watch, and for other research-driven cities, Eindhoven startups to watch and Groningen startups to watch.
Before you build, test your idea with real customers. Life sciences founders often leave marketing until a funding round depends on it, so start early: list your startup in the F/MS marketing directories, publish your startup press release, and write about your product with the F/MS AI SEO Tool or the AI SEO Blog so partners, investors and AI assistants can find you.
FAQ About Basel Startups to Watch in 2027
Which Basel startups should I watch in 2027?
Our verified list: Windward Bio, Alentis Therapeutics, Nuclidium, TOLREMO therapeutics, Synendos Therapeutics, Anaveon, Engimmune Therapeutics, Versameb, Axmed and Zoundream. Each gives a Basel or Allschwil address on its own website, checked in November 2026.
Which Basel startup signed the biggest deal recently?
Alentis Therapeutics. On 5 October 2026 CSL agreed to pay US$355 million upfront for a global partnership on its antibody lixudebart, with up to US$1.2 billion more in commercial milestones and shared profits.
Which Basel startup raised the most money recently?
Windward Bio announced a $165 million crossover financing on 4 May 2026, after a $200 million Series A in January 2025. Nuclidium closed a CHF 105 million Series B in May 2026.
Are there Basel startups outside biotech?
Yes, but fewer. Axmed runs a B2B marketplace for medicines in low- and middle-income countries, and Zoundream uses AI to analyse baby cries. Both are still in health. We did not find a Basel fintech or cleantech startup we could verify well enough to list.
Why did MindMaze, Evolytes and DPhi Space disappear from the list?
Their own sites and press releases place MindMaze and DPhi Space in Lausanne, and we found no Basel base for Evolytes, which is described as an Icelandic company. Five other names on the old list were not real companies.
Where can startups get support in Basel?
Basel Area Business & Innovation and its programmes, BaseLaunch for biotech, DayOne for healthtech, the Digital Accelerator Basel for digital startups, and Switzerland Innovation Park Basel Area for labs and offices.
How much funding can a Basel biotech startup get from BaseLaunch?
BaseLaunch says it offers up to CHF 500,000 in financing, plus access to partners, investors and labs. Its next application deadline is 8 January 2027.
Are there women founders in Basel's startup scene?
Yes. TOLREMO's CEO Stefanie Flückiger-Mangual co-founded the company, Ana Laguna Pradas co-founded Zoundream, and Prof. Jutta Heim chairs Synendos. The Fe/male Switch startup game is another way to practise building a startup.
What can founders learn from Basel startups?
Start from strong science or a later-stage asset, partner early with large companies, secure your supply chain, and be transparent where buyers distrust middlemen.
Where can I get a backlink by writing about my startup?
You can publish a guest post in one of the Fe/male Switch startup blogs, which rank in Google and in AI tools. Get a quality backlink.
About the Author
Violetta Bonenkamp, also known as MeanCEO, is an experienced startup founder with an impressive educational background including an MBA and four other higher education degrees. She has over 20 years of work experience across multiple countries, including 5 years as a solopreneur and serial entrepreneur. Throughout her startup experience she has applied for multiple startup grants at the EU level, in the Netherlands and Malta, and her startups received quite a few of those. She’s been living, studying and working in many countries around the globe and her extensive multicultural experience has influenced her immensely.
